RIGEL PHARMACEUTICALS INC (RIGL) Stock Fundamental Analysis
USA - NASDAQ:RIGL - US7665597024 - Common Stock
39.94 USD
+1.99 (+5.24%)
39.89 USD
-0.05 (-0.13%)
Taking everything into account, RIGL scores 7 out of 10 in our fundamental rating. RIGL was compared to 531 industry peers in the Biotechnology industry. RIGL is in great health and has no worries on liquidiy or solvency at all, but the profibility rating is only average. RIGL is evaluated to be cheap and growing strongly. This does not happen too often! These ratings would make RIGL suitable for value and growth investing!
1. Profitability
1.1 Basic Checks
RIGL had positive earnings in the past year.
In the past year RIGL had a positive cash flow from operations.
RIGL had negative earnings in 4 of the past 5 years.
In multiple years RIGL reported negative operating cash flow during the last 5 years.
1.2 Ratios
With an excellent Return On Assets value of 46.72%, RIGL belongs to the best of the industry, outperforming 99.62% of the companies in the same industry.
RIGL has a better Return On Equity (96.34%) than 99.25% of its industry peers.
With an excellent Return On Invested Capital value of 63.44%, RIGL belongs to the best of the industry, outperforming 99.62% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 46.72% | ||
| ROE | 96.34% | ||
| ROIC | 63.44% |
ROA(3y)-18.12%
ROA(5y)-18.4%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
RIGL's Profit Margin of 40.17% is amongst the best of the industry. RIGL outperforms 97.36% of its industry peers.
With an excellent Operating Margin value of 42.17%, RIGL belongs to the best of the industry, outperforming 98.68% of the companies in the same industry.
RIGL has a better Gross Margin (93.10%) than 92.66% of its industry peers.
In the last couple of years the Gross Margin of RIGL has declined.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 42.17% | ||
| PM (TTM) | 40.17% | ||
| GM | 93.1% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-3.38%
GM growth 5Y-1.87%
2. Health
2.1 Basic Checks
RIGL has a Return on Invested Capital (ROIC), which is well above the Cost of Capital (WACC), which means it is creating value.
RIGL has more shares outstanding than it did 1 year ago.
RIGL has less shares outstanding than it did 5 years ago.
The debt/assets ratio for RIGL has been reduced compared to a year ago.
2.2 Solvency
RIGL has an Altman-Z score of -0.80. This is a bad value and indicates that RIGL is not financially healthy and even has some risk of bankruptcy.
RIGL has a Altman-Z score of -0.80. This is comparable to the rest of the industry: RIGL outperforms 57.63% of its industry peers.
RIGL has a debt to FCF ratio of 0.88. This is a very positive value and a sign of high solvency as it would only need 0.88 years to pay back of all of its debts.
The Debt to FCF ratio of RIGL (0.88) is better than 94.16% of its industry peers.
RIGL has a Debt/Equity ratio of 0.25. This is a healthy value indicating a solid balance between debt and equity.
RIGL has a worse Debt to Equity ratio (0.25) than 68.74% of its industry peers.
Although RIGL does not score too well on debt/equity it has very limited outstanding debt, which is well covered by the FCF. We will not put too much weight on the debt/equity number as it may be because of low equity, which could be a consequence of a share buyback program for instance. This needs to be investigated.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.25 | ||
| Debt/FCF | 0.88 | ||
| Altman-Z | -0.8 |
ROIC/WACC7.18
WACC8.83%
2.3 Liquidity
RIGL has a Current Ratio of 2.28. This indicates that RIGL is financially healthy and has no problem in meeting its short term obligations.
With a Current ratio value of 2.28, RIGL is not doing good in the industry: 71.94% of the companies in the same industry are doing better.
RIGL has a Quick Ratio of 2.14. This indicates that RIGL is financially healthy and has no problem in meeting its short term obligations.
RIGL has a worse Quick ratio (2.14) than 71.37% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.28 | ||
| Quick Ratio | 2.14 |
3. Growth
3.1 Past
RIGL shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 4307.14%, which is quite impressive.
The Revenue has grown by 79.13% in the past year. This is a very strong growth!
The Revenue has been growing by 24.77% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)4307.14%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%108.57%
Revenue 1Y (TTM)79.13%
Revenue growth 3Y6.31%
Revenue growth 5Y24.77%
Sales Q2Q%25.59%
3.2 Future
The Earnings Per Share is expected to grow by 29.86% on average over the next years. This is a very strong growth
The Revenue is expected to grow by 14.40% on average over the next years. This is quite good.
EPS Next Y503.1%
EPS Next 2Y102.44%
EPS Next 3Y61.96%
EPS Next 5Y29.86%
Revenue Next Year62.09%
Revenue Next 2Y26.39%
Revenue Next 3Y18.97%
Revenue Next 5Y14.4%
3.3 Evolution
The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
4. Valuation
4.1 Price/Earnings Ratio
RIGL is valuated cheaply with a Price/Earnings ratio of 6.47.
98.12% of the companies in the same industry are more expensive than RIGL, based on the Price/Earnings ratio.
Compared to an average S&P500 Price/Earnings ratio of 26.34, RIGL is valued rather cheaply.
Based on the Price/Forward Earnings ratio of 10.37, the valuation of RIGL can be described as reasonable.
RIGL's Price/Forward Earnings ratio is rather cheap when compared to the industry. RIGL is cheaper than 97.93% of the companies in the same industry.
RIGL is valuated cheaply when we compare the Price/Forward Earnings ratio to 34.43, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 6.47 | ||
| Fwd PE | 10.37 |
4.2 Price Multiples
98.68% of the companies in the same industry are more expensive than RIGL, based on the Enterprise Value to EBITDA ratio.
98.49% of the companies in the same industry are more expensive than RIGL, based on the Price/Free Cash Flow ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 10.52 | ||
| EV/EBITDA | 4.24 |
4.3 Compensation for Growth
The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
RIGL has a very decent profitability rating, which may justify a higher PE ratio.
RIGL's earnings are expected to grow with 61.96% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.01
PEG (5Y)N/A
EPS Next 2Y102.44%
EPS Next 3Y61.96%
5. Dividend
5.1 Amount
RIGL does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
39.94
+1.99 (+5.24%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners80.02%
Inst Owner Change0.45%
Ins Owners2.58%
Ins Owner Change1.25%
Market Cap716.52M
Revenue(TTM)282.08M
Net Income(TTM)113.30M
Analysts76.67
Price Target39.1 (-2.1%)
Short Float %19.93%
Short Ratio5.23
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)46.05%
Min EPS beat(2)24.64%
Max EPS beat(2)67.46%
EPS beat(4)4
Avg EPS beat(4)188.12%
Min EPS beat(4)24.64%
Max EPS beat(4)592.43%
EPS beat(8)7
Avg EPS beat(8)242.36%
EPS beat(12)11
Avg EPS beat(12)181.29%
EPS beat(16)14
Avg EPS beat(16)138.58%
Revenue beat(2)2
Avg Revenue beat(2)11.07%
Min Revenue beat(2)10.05%
Max Revenue beat(2)12.08%
Revenue beat(4)4
Avg Revenue beat(4)12.62%
Min Revenue beat(4)9.15%
Max Revenue beat(4)19.17%
Revenue beat(8)7
Avg Revenue beat(8)10.41%
Revenue beat(12)11
Avg Revenue beat(12)14.43%
Revenue beat(16)12
Avg Revenue beat(16)11.18%
PT rev (1m)0%
PT rev (3m)13.61%
EPS NQ rev (1m)0%
EPS NQ rev (3m)256.15%
EPS NY rev (1m)0%
EPS NY rev (3m)380.48%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)22.41%
Revenue NY rev (1m)0%
Revenue NY rev (3m)39.78%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 6.47 | ||
| Fwd PE | 10.37 | ||
| P/S | 2.54 | ||
| P/FCF | 10.52 | ||
| P/OCF | 10.51 | ||
| P/B | 6.09 | ||
| P/tB | 7.77 | ||
| EV/EBITDA | 4.24 |
EPS(TTM)6.17
EY15.45%
EPS(NY)3.85
Fwd EY9.65%
FCF(TTM)3.8
FCFY9.51%
OCF(TTM)3.8
OCFY9.52%
SpS15.72
BVpS6.56
TBVpS5.14
PEG (NY)0.01
PEG (5Y)N/A
Graham Number30.17
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 46.72% | ||
| ROE | 96.34% | ||
| ROCE | 80.3% | ||
| ROIC | 63.44% | ||
| ROICexc | 854.98% | ||
| ROICexgc | N/A | ||
| OM | 42.17% | ||
| PM (TTM) | 40.17% | ||
| GM | 93.1% | ||
| FCFM | 24.16% |
ROA(3y)-18.12%
ROA(5y)-18.4%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-3.38%
GM growth 5Y-1.87%
F-Score7
Asset Turnover1.16
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.25 | ||
| Debt/FCF | 0.88 | ||
| Debt/EBITDA | 0.25 | ||
| Cap/Depr | 1.57% | ||
| Cap/Sales | 0.01% | ||
| Interest Coverage | 17.61 | ||
| Cash Conversion | 56.17% | ||
| Profit Quality | 60.14% | ||
| Current Ratio | 2.28 | ||
| Quick Ratio | 2.14 | ||
| Altman-Z | -0.8 |
F-Score7
WACC8.83%
ROIC/WACC7.18
Cap/Depr(3y)424.8%
Cap/Depr(5y)301.24%
Cap/Sales(3y)4.48%
Cap/Sales(5y)3%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)4307.14%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%108.57%
EPS Next Y503.1%
EPS Next 2Y102.44%
EPS Next 3Y61.96%
EPS Next 5Y29.86%
Revenue 1Y (TTM)79.13%
Revenue growth 3Y6.31%
Revenue growth 5Y24.77%
Sales Q2Q%25.59%
Revenue Next Year62.09%
Revenue Next 2Y26.39%
Revenue Next 3Y18.97%
Revenue Next 5Y14.4%
EBIT growth 1Y1151.72%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year470.56%
EBIT Next 3Y88.04%
EBIT Next 5YN/A
FCF growth 1Y286.79%
FCF growth 3Y80.89%
FCF growth 5YN/A
OCF growth 1Y418.44%
OCF growth 3Y74.92%
OCF growth 5YN/A
RIGEL PHARMACEUTICALS INC / RIGL FAQ
What is the ChartMill fundamental rating of RIGEL PHARMACEUTICALS INC (RIGL) stock?
ChartMill assigns a fundamental rating of 7 / 10 to RIGL.
Can you provide the valuation status for RIGEL PHARMACEUTICALS INC?
ChartMill assigns a valuation rating of 9 / 10 to RIGEL PHARMACEUTICALS INC (RIGL). This can be considered as Undervalued.
Can you provide the profitability details for RIGEL PHARMACEUTICALS INC?
RIGEL PHARMACEUTICALS INC (RIGL) has a profitability rating of 6 / 10.
Can you provide the expected EPS growth for RIGL stock?
The Earnings per Share (EPS) of RIGEL PHARMACEUTICALS INC (RIGL) is expected to grow by 503.1% in the next year.